TISSUE & FFPE COHORT COLLECTIONS
Lung cancer tissue microarrays & FFPE blocks
Explore NSCLC and SCLC arrays by histology, molecular profile and treatment context. Compare adenocarcinoma and squamous cell carcinoma collections, matched tissue, and selected clinical or molecular datasets. For FFPE blocks, share your tissue and study requirements with our team.
THE ARRAYS
Lung cancer arrays (19)
Collection types in this TMA catalog
Explore the tissue composition and sampling groups represented in these arrays.
NSCLC (ADC & SCC) stages IIIA, IIIB & IV with histopath and optional PD-L1 (22C3) IHC data (TA4305)
- Approx. cores
- 100
- Approx. donors
- 100
- Core diameter
- 1mm
- Clinical follow-up
- Not listed
- Molecular data
- Available
NSCLC (ADC & SCC) stages IIIB & IV with histopath and optional follow up & PD-L1 (22C3) IHC data (TA4307)
- Approx. cores
- 80
- Approx. donors
- 80
- Core diameter
- 1mm
- Clinical follow-up
- Available
- Molecular data
- Available
NSCLC (ADC & SCC) with histopath data, PD-L1(22C3) status & Oncomine Precision Assay NGS data – optional follow up data (TA4327)
- Approx. cores
- 106
- Approx. donors
- 106
- Core diameter
- 1mm
- Clinical follow-up
- Available
- Molecular data
- Available
NSCLC (ADC & SCC) with low, moderate & high PD-L1(22C3) expression with histopath data – optional follow up data (TA4333)
- Approx. cores
- 36
- Approx. donors
- 36
- Core diameter
- 1mm
- Clinical follow-up
- Available
- Molecular data
- Available
NSCLC (ADC) with follow up, PD-L1(22C3) & MSI data (TA2855)
- Approx. cores
- 70
- Approx. donors
- 70
- Core diameter
- 1mm
- Clinical follow-up
- Available
- Molecular data
- Available
NSCLC (EGFR mutated & wild type) with histopath data (TA4322)
- Approx. cores
- 44
- Approx. donors
- 44
- Core diameter
- 1mm
- Clinical follow-up
- Not listed
- Molecular data
- Available
NSCLC (KRAS mutated & wild type) with histopath data (TA4323)
- Approx. cores
- 54
- Approx. donors
- 54
- Core diameter
- 1mm
- Clinical follow-up
- Not listed
- Molecular data
- Available
NSCLC (SCC) with histopath data (TA3112)
- Approx. cores
- 65
- Approx. donors
- 65
- Core diameter
- 1mm
- Clinical follow-up
- Not listed
- Molecular data
- Not listed
NSCLC donor matched pre & post treatment samples with follow up data (TA3111)
- Approx. cores
- 28
- Approx. donors
- 14
- Core diameter
- 1mm
- Clinical follow-up
- Available
- Molecular data
- Not listed
NSCLC post-treatment samples with follow up, KRAS & EGFR mutation data (TA3150)
- Approx. cores
- 50
- Approx. donors
- 25
- Core diameter
- 1mm
- Clinical follow-up
- Available
- Molecular data
- Available
NSCLC primary & matched nodal mets with histopath data (TA4303)
- Approx. cores
- 66
- Approx. donors
- 66
- Core diameter
- 1mm
- Clinical follow-up
- Not listed
- Molecular data
- Not listed
NSCLC Stage III_IV with follow up data (TA1855)
- Approx. cores
- 100
- Approx. donors
- 50
- Core diameter
- 1mm
- Clinical follow-up
- Available
- Molecular data
- Not listed
NSCLC with 2nd line IO follow up & optional RNAseq, GeoMx (protein & RNA panels), DAB IHC data (TA4301)
- Approx. cores
- 38
- Approx. donors
- 38
- Core diameter
- 1mm
- Clinical follow-up
- Available
- Molecular data
- Available
NSCLC with follow up & PD-L1(22C3) IHC data (TA4311)
- Approx. cores
- 126
- Approx. donors
- 126
- Core diameter
- 1mm
- Clinical follow-up
- Available
- Molecular data
- Available
NSCLC with histopath data & matched double-spun plasma
- Approx. cores
- 90
- Approx. donors
- 40
- Core diameter
- 1mm
- Clinical follow-up
- Not listed
- Molecular data
- Not listed
NSCLC with IO (Pembro/Nivo) follow up data, pre treatment and post IO treatment (not donor matched)
- Approx. cores
- 25
- Approx. donors
- 25
- Core diameter
- 1mm
- Clinical follow-up
- Available
- Molecular data
- Available
NSCLC with SOC chemo follow up & optional GeoMx (protein panel) data (TA4302)
- Approx. cores
- 48
- Approx. donors
- 48
- Core diameter
- 1mm
- Clinical follow-up
- Available
- Molecular data
- Available
RNAscope pre-qualified Lung cancer TMA (SCLC, NSCLC (ADC), NSCLC (SCC), histopath data, sub-set with EGFR mutation status (TA3168)
- Approx. cores
- 56
- Approx. donors
- 56
- Core diameter
- 1mm
- Clinical follow-up
- Not listed
- Molecular data
- Not listed
Small Cell Lung Cancer (SCLC) with follow up data (TA2893)
- Approx. cores
- 20
- Approx. donors
- 20
- Core diameter
- 1mm
- Clinical follow-up
- Available
- Molecular data
- Not listed
No arrays match these filters
Try another search or clear the filters to see this collection.
Data labels reflect the catalog record. Review each product and datasheet for case-level coverage. Array counts do not indicate stock availability.
FFPE TISSUE BLOCKS
Lung cancer FFPE blocks for your study
Explore NSCLC FFPE cohorts defined by EGFR, ROS1, PD-L1 or treatment setting, alongside separate small-cell lung cancer and neuroendocrine carcinoma profiles.
FFPE blocks are requested by inquiry. Our team confirms tissue availability, donor matching and data coverage for your study.
Explore NSCLC FFPE cohort profiles
Collection features
- Advanced disease (III/IV)
- Longitudinal data
- Primary & matched metastases
- Pre / post standard-of-care treatment
- Pre / post immunotherapy
Features vary by profile and donor; confirm the required coverage for your study.
EGFR-mutated locally advanced or metastatic disease
Inquire about this cohortEGFR-mutated, MET-positive locally advanced or metastatic disease
Inquire about this cohortEGFR exon 20 insertion mutation
Inquire about this cohortTKI-treatment-naïve ROS1-positive disease
Inquire about this cohortAdvanced or metastatic NSCLC
Inquire about this cohortPD-L1 <50% metastatic NSCLC
Inquire about this cohortPD-L1 tumor-cell expression ≥1% non-squamous NSCLC
Inquire about this cohortPD-L1 tumor-cell expression ≥1% squamous NSCLC
Inquire about this cohortPD-L1 tumor-cell expression ≥50% locally advanced or metastatic non-squamous NSCLC
Inquire about this cohortBefore or after immunotherapy / checkpoint inhibitor treatment
Inquire about this cohortExplore Small-cell lung cancer & neuroendocrine carcinoma FFPE cohort profiles
Relapsed / refractory small-cell lung cancer
Inquire about this cohortExtensive-stage small-cell lung cancer
Inquire about this cohortPoorly differentiated neuroendocrine carcinoma, including SCLC, large-cell neuroendocrine carcinoma (LCNEC) and extrapulmonary NEC
Inquire about this cohortProfiles describe documented collections, not live inventory. Features vary by profile and donor. Pre/post treatment collections are not necessarily donor-matched; availability and required coverage are confirmed for your study.
SELECTING YOUR ARRAY
Match lung histology, markers and treatment context
A marker-defined array and a treatment-follow-up array answer different selection needs. Review the tissue and the associated records together.
Histology and molecular groups
TA2893 is a small cell lung cancer collection with follow-up. For NSCLC, TA4322 includes EGFR-mutated and wild-type tissue, while TA4323 uses KRAS status to define its listed groups. Histopathology and molecular coverage vary by array.
Treatment setting and donor matching
TA3111 contains donor-matched pre- and post-treatment NSCLC samples. Other pre/post collections are explicitly not donor matched. TA4301 is listed with second-line immunotherapy follow-up; the treatment setting should be checked at case level.
Included records versus optional datasets
TA4301 lists RNA-seq, GeoMx protein/RNA and DAB IHC data as optional. TA4327 lists PD-L1 and Oncomine Precision Assay NGS data with optional follow-up. Do not assume one array's data package applies to another.
















